Sophia Genetics reveals the most advanced artificial intelligence platform worldwide collective

Sophia Genetics reveals the most advanced artificial intelligence platform worldwide collective -

Sophia Genetics, the world leader in medicine based on data, today unveiled SOPHIA, intelligence the most advanced collective artificial world (AI) for data-Driven Medicine. Technology state-of-the-art, SOPHIA learns continuously from thousands of genomic profiles and expert knowledge of patients for improved diagnostics and patient treatment. The incomparable analytical powers SOPHIA based on the common genomic information Sophia DDM ^® , the largest clinical genomics community in the world for molecular diagnosis, gathering to date, 170 hospitals in 28 countries.

Today, Sophia Genetics also revealed results showing how SOPHIA managed to get a 98% match with forecasts varying pathogenicity expert clinicians for BRCA mutations, which carry a potential risk of susceptibility breast cancer. To obtain such a quality result, AI from the Swiss technology company examined data from thousands of genomic tests for patients on the basis of information pooled by hospitals in Sophia DDM ^® learn to predict the pathogenicity genomic variants in almost the same way a clinical expert made, and changes as new data became available.

an initial match 85% was obtained with 10,000 patients analyzed, improved 96% match with 20,000 tests and 98% with classifications by clinical experts. Final results are based on the genomic profiles of 30,000 patients, containing 28,000 unique genomic variants. The variants examined by SOPHIA were identified and classified by three advanced proprietary and patented technologies Sophia Genetics, PEPPER ™, MUSKAT ™ and MOKA ™, ensuring 99.9% specificity and sensitivity that oncologists, clinicians and medical specialists must report in confidence clinical genomic variants to their patients.

sophia revolutionary technology will soon be available for hospitals and clinicians members Sophia DDM ^® community. Moving forward, the sharing secure and private genomic profiles of more patients on Sophia DDM ^® allow similar advanced SOPHIA for 40 other diseases of the genome; oncology, hereditary cancers, cardiology, metabolic disorders and pediatrics, and the advent of a true medicine based on data for patients.

Speaking of this breakthrough in the diagnosis and breast cancer treatment, but also for medicine based on the data set, Jurgi Camblong, CEO and co-founder of Sophia Genetics stated:

I am proud to announce that Sophia Genetics is the first company with such power genomic classification variant in molecular diagnostics. SOPHIA facilitates clinical interpretation and artificial intelligence features give medical experts more time to focus on the study of complex cases. Moving forward, we will use this technology state-of-the-art of applying predictive power of the SOPHIA other supported applications on our clinical genomics platform Sophia DDM ^® . We are already involved in better and faster diagnosis of 0 patients each day and we expect results SOPHIA presented today to significantly increase this number by allowing clinicians to deliver faster and better diagnoses and patients to benefit from better treatments.